Table 1

Baseline characteristics and disease activity of patient populations

Placebo once daily (N=98)1 mg once daily (N=49)2 mg once daily (N=52)4 mg once daily (N=52)8 mg once daily (N=50)
Age, years*49±1253±1151±1353±1053±11
Gender, % female8786857182
Duration of RA, years5.4±4.35.5±3.95.5±4.45.3±4.56.6±5.0
Anti-CCP antibody,† % positive6276677174
RF‡,% positive6571677780
Methotrexate dose, mg/week16.3±4.318.2±13.414.9±4.116.3±4.815.7±4.2
Concomitant cDMARDs for RA, % patients
Prednisone use, % patients5243523858
Duration of morning joint stiffness, minutes101.7±110.791.4±78.473.1±42.2103.9±145.195.8±97.8
Tender joints (68 count)22.2±12.121.4±10.923.0±12.619.9±12.724.4±13.8
Swollen joints (66 count)15.8±8.615.2±6.617.0±9.314.8±7.516.1±7.9
Tender joints (28 count)14.1±6.214.0±5.514.5±6.413.1±6.415.7±6.2
Swollen joints (28 count)11.8±5.411.9±4.612.1±6.011.2±4.811.6±4.6
hsCRP, mg/L¶14.0±23.511.2±12.412.0±22.111.4±16.914.3±15.6
ESR, mm/h39.9±20.938.2±17.636.5±14.635.4±17.243.3±18.2
  • *Data reported as mean values±SD unless otherwise indicated.

  • †Anti-CCP antibody positivity (>upper limit of normal (ULN)=5 EU/mL).

  • ‡RF positivity (>ULN=14 IU/mL).

  • §Scores on the HAQ-DI range from 0 to 3, with higher scores indicating greater disability.

  • ¶hsCRP (ULN=3 mg/L).

  • Anti-CCP, anticyclic citrullinated peptide; CDAI, clinical disease activity index; cDMARDs, conventional disease-modifying antirheumatic drugs; DAS28-ESR, Disease Activity Score for 28-joint counts based on the ESR; DAS28-hsCRP, Disease Activity Score for 28-joint counts based on the hsCRP level; DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire–Disability Index; hsCRP, high-sensitivity C reactive protein; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, simplified disease activity index.